Key Points - Eli Lilly leads in the GLP-1 drug space with its shot-based offerings Mounjaro and Zepbound. - Rival drugmaker Novo Nordisk has now introduced a pill version of its GLP-1 weight loss drug. - Eli Lilly's valuation looks stretched at this point -- both against the industry and overall…
Continue reading...